Zhou Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zhou Chen has a total of 95 co-authors. Here are the top co-authors by number of shared publications:
- Libin Liu
Department of Endocrinology, Fujian Union Hospital, Fuzhou, China
8 shared publications Libin Liu
Department of Endocrinology and Metabolism, Fujian Medical University Union Hospital, Fuzhou 350001, China
5 shared publicationsYu Zhou
School of Pharmacy, Fujian Medical University, Fuzhou, China
5 shared publicationsYunzhen Xie
School of Pharmacy, Fujian Medical University, Fuzhou 350122, China
5 shared publicationsLele Zhou
School of Pharmacy, Fujian Medical University, Fuzhou 350122, China
4 shared publicationsMeihua Zhong
School of Pharmacy, Fujian Medical University, Fuzhou 350122, China
4 shared publications
Latest Publications
- Open Access
- 6 July 2026
- Published by Wiley in Advanced Science
- Vol. 13 (52) , e76302
Palmitoylation of PSD‐95 Orchestrates Learning‐Dependent Metaplasticity in the Amygdala and Fear Memory
Palmitoylation has been implicated in learning and memory processes, yet its precise role and underlying mechanisms remain poorly understood. Here, we report a novel role of palmitoylation in regulating amygdalar synaptic plasticity and fear memory, involving the regulation of palmitate cycling on PSD‐95. Using a series of multi‐methodological experiments, we demonstrated that conditioned fear learning impairs amygdalar metaplasticity—an effect not observed in the hippocampus. Furthermore, PSD‐95 recruits LTP‐like mechanisms at lateral amygdala (LA) synapses, and its palmitoylation is critically involved in fear memory expression. Notably, PSD‐95 palmitoylation contributes to the occlusion of LA‐LTP following fear conditioning. Mechanistically, DHHC2 drives PSD‐95 palmitoylation and modulates LA synaptic plasticity following fear conditioning, whereas PICK1 facilitates the activity‐dependent trafficking of DHHC2 to PSD‐95 at synapses. Collectively, these findings highlight the PICK1‐DHHC2‐PSD‐95 pathway as a critical regulator of learning‐dependent metaplasticity in the LA, which occludes further HFS‐induced LTP while promoting fear memory expression.
- 6 July 2026
- Published by Wiley in Advanced Science
- Vol. 13 (52) , e76302
Open AccessPalmitoylation of PSD‐95 Orchestrates Learning‐Dependent Metaplasticity in the Amygdala and Fear Memory
Palmitoylation has been implicated in learning and memory processes, yet its precise role and underlying mechanisms remain poorly understood. Here, we report a novel role of palmitoylation in regulating amygdalar synaptic plasticity and fear memory, involving the regulation of palmitate cycling on PSD‐95. Using a series of multi‐methodological experiments, we demonstrated that conditioned fear learning impairs amygdalar metaplasticity—an effect not observed in the hippocampus. Furthermore, PSD‐95 recruits LTP‐like mechanisms at lateral amygdala (LA) synapses, and its palmitoylation is critically involved in fear memory expression. Notably, PSD‐95 palmitoylation contributes to the occlusion of LA‐LTP following fear conditioning. Mechanistically, DHHC2 drives PSD‐95 palmitoylation and modulates LA synaptic plasticity following fear conditioning, whereas PICK1 facilitates the activity‐dependent trafficking of DHHC2 to PSD‐95 at synapses. Collectively, these findings highlight the PICK1‐DHHC2‐PSD‐95 pathway as a critical regulator of learning‐dependent metaplasticity in the LA, which occludes further HFS‐induced LTP while promoting fear memory expression.
- Open Access
- 26 March 2026
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 17
Multi-omics profiling implicates gut microbiota-sphingolipid interplay in the neuroprotective effects of semaglutide on diabetic cognitive impairment
Background: The gut microbiome is a critical regulator of host health, but how it mediates the therapeutic effects of drugs targeting neurodegenerative diseases like diabetic cognitive impairment (DCI) is unclear. Here, we investigated whether the neuroprotective effects of the GLP-1 agonist semaglutide (SE) are linked to its modulation of the gut-brain axis. Methods: We used an integrative multi-omics approach in a mouse model of DCI. We combined fecal shotgun metagenomics and targeted bile acid profiling with cerebral proteomics and metabolomics to characterize the gut-brain crosstalk following a 12-week SE treatment. Animal behavior, neuronal survival and synaptic integrity were assessed to confirm therapeutic efficacy. Results: SE treatment reversed cognitive deficits, rescued hippocampal neuronal loss, and restored synaptic integrity in diabetic mice. At the ecosystem level, metagenomics revealed that SE treatment profoundly remodeled the gut microbiota, enhancing microbial α-diversity, enriched beneficial genera ( Bacteroides , Barnesiella ), and depleted the pro-inflammatory genus Desulfovibrio . This microbial shift was associated with normalized fecal and cerebral bile acid profiles. Mechanistically, our analysis implicated a dysregulated sphingolipid pathway in the DCI brain, characterized by the upregulation of the transporter ATP-binding cassette transporter A2 (ABCA2) and the enzymes sphingosine-1-phosphate phosphatase 1 (SGPP1) and ceramide synthase 2 (CERS2). SE treatment dynamically modulated this pathway: it downregulated ABCA2 in a potentially weight-independent manner and SGPP1 in a weight-dependent fashion, linked to the normalization of cerebral bile acid profiles. In contrast, CERS2, a robust marker of disease severity, was not altered by SE. Conclusion: Our study uncovers a novel “gut microbiota–bile acid–sphingolipid” axis in DCI and suggests that SE acts via a dual mechanism. It drives a weight-dependent restoration of the gut-brain axis, normalizing microbial and bile acid profiles to regulate SGPP1, while also exerting weight-independent effects, potentially through direct modulation of targets like ABCA2. This work highlights the gut microbiome as a key component in the therapeutic action of SE and reveals the multifaceted nature of its neuroprotective effects.
- 26 March 2026
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 17
Open AccessMulti-omics profiling implicates gut microbiota-sphingolipid interplay in the neuroprotective effects of semaglutide on diabetic cognitive impairment
Background: The gut microbiome is a critical regulator of host health, but how it mediates the therapeutic effects of drugs targeting neurodegenerative diseases like diabetic cognitive impairment (DCI) is unclear. Here, we investigated whether the neuroprotective effects of the GLP-1 agonist semaglutide (SE) are linked to its modulation of the gut-brain axis. Methods: We used an integrative multi-omics approach in a mouse model of DCI. We combined fecal shotgun metagenomics and targeted bile acid profiling with cerebral proteomics and metabolomics to characterize the gut-brain crosstalk following a 12-week SE treatment. Animal behavior, neuronal survival and synaptic integrity were assessed to confirm therapeutic efficacy. Results: SE treatment reversed cognitive deficits, rescued hippocampal neuronal loss, and restored synaptic integrity in diabetic mice. At the ecosystem level, metagenomics revealed that SE treatment profoundly remodeled the gut microbiota, enhancing microbial α-diversity, enriched beneficial genera ( Bacteroides , Barnesiella ), and depleted the pro-inflammatory genus Desulfovibrio . This microbial shift was associated with normalized fecal and cerebral bile acid profiles. Mechanistically, our analysis implicated a dysregulated sphingolipid pathway in the DCI brain, characterized by the upregulation of the transporter ATP-binding cassette transporter A2 (ABCA2) and the enzymes sphingosine-1-phosphate phosphatase 1 (SGPP1) and ceramide synthase 2 (CERS2). SE treatment dynamically modulated this pathway: it downregulated ABCA2 in a potentially weight-independent manner and SGPP1 in a weight-dependent fashion, linked to the normalization of cerebral bile acid profiles. In contrast, CERS2, a robust marker of disease severity, was not altered by SE. Conclusion: Our study uncovers a novel “gut microbiota–bile acid–sphingolipid” axis in DCI and suggests that SE acts via a dual mechanism. It drives a weight-dependent restoration of the gut-brain axis, normalizing microbial and bile acid profiles to regulate SGPP1, while also exerting weight-independent effects, potentially through direct modulation of targets like ABCA2. This work highlights the gut microbiome as a key component in the therapeutic action of SE and reveals the multifaceted nature of its neuroprotective effects.
- 21 March 2026
- Published by Elsevier in Biochemical Pharmacology
- Vol. 249, 117917
CypA inhibition attenuates diabetic hypoglycemia-induced cognitive impairment via the CD147/NF-κB/MMP-9 pathway
- 21 March 2026
- Published by Elsevier in Biochemical Pharmacology
- Vol. 249, 117917
CypA inhibition attenuates diabetic hypoglycemia-induced cognitive impairment via the CD147/NF-κB/MMP-9 pathway
- 3 March 2026
- Published by Elsevier in Toxicology Letters
- Vol. 419, 111872
Tripchlorolide-induced reversible impairment of male fertility and the involvement of PI3K/Akt/mTOR signaling
- 3 March 2026
- Published by Elsevier in Toxicology Letters
- Vol. 419, 111872
Tripchlorolide-induced reversible impairment of male fertility and the involvement of PI3K/Akt/mTOR signaling
- 9 January 2026
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1014, 178535
Lactoferrin ameliorates social isolation-induced cognitive decline by modulating mitochondrial function and ferroptosis
- 9 January 2026
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1014, 178535
Lactoferrin ameliorates social isolation-induced cognitive decline by modulating mitochondrial function and ferroptosis
- 4 October 2025
- Published by Elsevier in Journal of Chromatography B
- Vol. 1267, 124805
Pharmacokinetics and tissue distribution of tripchlorolide in rodents using liquid chromatography tandem mass spectrometry
- 4 October 2025
- Published by Elsevier in Journal of Chromatography B
- Vol. 1267, 124805
Pharmacokinetics and tissue distribution of tripchlorolide in rodents using liquid chromatography tandem mass spectrometry
- 18 July 2025
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1003, 177974
Everolimus alleviates cognitive dysfunction in 5×FAD mice by regulating mitochondrial function and oxidative stress
- 18 July 2025
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1003, 177974
Everolimus alleviates cognitive dysfunction in 5×FAD mice by regulating mitochondrial function and oxidative stress
- Open Access
- 31 October 2024
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1500105
Epileptic seizures induced by pentylenetetrazole kindling accelerate Alzheimer-like neuropathology in 5×FAD mice
Clinical studies have shown that epileptic seizures worsen Alzheimer’s disease (AD) pathology and related cognitive deficits; however, the underlying mechanism is unclear. To assess the effects of seizures on the progression of AD, chronic temporal lobe epilepsy was induced in five familial AD mutation (5×FAD) mice by kindling with the chemoconvulsant pentylenetetrazole (PTZ) at 3–3.5 months of age. The amyloidogenic pathway, tauopathy, synaptic damage, neuronal death, neurological inflammatory response and associated kinase signaling pathway dysregulation were examined at 9 months of age. We found that APP, p-APP, BACE1, Aβ and kinase-associated p-tau levels were elevated after PTZ kindling in 5×FAD mice. In addition, PTZ kindling exacerbated hippocampal synaptic damage and neuronal cell death, as determined by scanning electron microscopy and terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling (TUNEL) staining, respectively. Finally, the levels of the neuroinflammation markers GFAP and Iba1, as well as the inflammatory cytokine IL-1β, were increased after PTZ insult. PTZ kindling profoundly exacerbated extracellular regulated kinase (ERK)-death-associated protein kinase (DAPK) signaling pathway overactivation, and acute ERK inhibitor treatment downregulated Aβ production and p-APP and p-tau levels in epileptic 5×FAD mice. In addition, long-term use of the antiseizure drug carbamazepine (CBZ) alleviated seizure-induced accelerated amyloid and tau pathology and ERK-DAPK overactivation in 5×FAD mice. Collectively, these results demonstrate that seizure-induced increases in AD-like neuropathology in 5×FAD mice are partially regulated by the ERK-DAPK pathway, suggesting that the ERK-DAPK axis could be a new therapeutic target for the treatment of AD patients with comorbid seizures.
- 31 October 2024
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1500105
Open AccessEpileptic seizures induced by pentylenetetrazole kindling accelerate Alzheimer-like neuropathology in 5×FAD mice
Clinical studies have shown that epileptic seizures worsen Alzheimer’s disease (AD) pathology and related cognitive deficits; however, the underlying mechanism is unclear. To assess the effects of seizures on the progression of AD, chronic temporal lobe epilepsy was induced in five familial AD mutation (5×FAD) mice by kindling with the chemoconvulsant pentylenetetrazole (PTZ) at 3–3.5 months of age. The amyloidogenic pathway, tauopathy, synaptic damage, neuronal death, neurological inflammatory response and associated kinase signaling pathway dysregulation were examined at 9 months of age. We found that APP, p-APP, BACE1, Aβ and kinase-associated p-tau levels were elevated after PTZ kindling in 5×FAD mice. In addition, PTZ kindling exacerbated hippocampal synaptic damage and neuronal cell death, as determined by scanning electron microscopy and terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling (TUNEL) staining, respectively. Finally, the levels of the neuroinflammation markers GFAP and Iba1, as well as the inflammatory cytokine IL-1β, were increased after PTZ insult. PTZ kindling profoundly exacerbated extracellular regulated kinase (ERK)-death-associated protein kinase (DAPK) signaling pathway overactivation, and acute ERK inhibitor treatment downregulated Aβ production and p-APP and p-tau levels in epileptic 5×FAD mice. In addition, long-term use of the antiseizure drug carbamazepine (CBZ) alleviated seizure-induced accelerated amyloid and tau pathology and ERK-DAPK overactivation in 5×FAD mice. Collectively, these results demonstrate that seizure-induced increases in AD-like neuropathology in 5×FAD mice are partially regulated by the ERK-DAPK pathway, suggesting that the ERK-DAPK axis could be a new therapeutic target for the treatment of AD patients with comorbid seizures.
- Open Access
- 1 February 2024
- Published by Elsevier in Behavioural Brain Research
- Vol. 463, 114889
Mitophagy activation by rapamycin enhances mitochondrial function and cognition in 5×FAD mice
- 1 February 2024
- Published by Elsevier in Behavioural Brain Research
- Vol. 463, 114889
Open AccessMitophagy activation by rapamycin enhances mitochondrial function and cognition in 5×FAD mice
- 11 November 2023
- Published by Elsevier in Molecular and Cellular Endocrinology
- Vol. 580, 112109
Activation of mitophagy improves cognitive dysfunction in diabetic mice with recurrent non-severe hypoglycemia
- 11 November 2023
- Published by Elsevier in Molecular and Cellular Endocrinology
- Vol. 580, 112109
Activation of mitophagy improves cognitive dysfunction in diabetic mice with recurrent non-severe hypoglycemia